Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.41 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25033144 | 1.00 | UGT2B17 (0.49) | UGT2B17NLRP3ELAVL1MAPTPGR | |
| SCHEMBL22010660 | 1.00 | UGT2B17 (0.49) | UGT2B17NLRP3ELAVL1MAPTPGR | |
| SCHEMBL22011164 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3 | |
| SCHEMBL20681026 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3 | |
| SCHEMBL25033139 | 0.79 | NLRP3 (0.43) | UGT2B17NLRP3 | |
| SCHEMBL22002719 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3MAPTLMNASLC5A1 | |
| SCHEMBL24960215 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3MAPTLMNASLC5A1 | |
| SCHEMBL22002766 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3MAPTLMNASLC5A1 | |
| SCHEMBL21893592 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3 | |
| SCHEMBL21892906 | 0.79 | UGT2B17 (0.41) | UGT2B17NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102098-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |